OraSure Technologies, Inc. (NASDAQ:OSUR) Downgraded by BidaskClub

BidaskClub lowered shares of OraSure Technologies, Inc. (NASDAQ:OSUR) from a buy rating to a hold rating in a research note released on Monday, July 31st.

OSUR has been the subject of several other reports. Jefferies Group LLC boosted their price objective on OraSure Technologies from $12.00 to $16.00 and gave the stock a buy rating in a research report on Thursday, May 4th. Zacks Investment Research cut OraSure Technologies from a buy rating to a hold rating in a report on Wednesday, April 12th. Canaccord Genuity boosted their target price on shares of OraSure Technologies from $15.00 to $18.00 and gave the company a buy rating in a research note on Wednesday, June 28th. Finally, Stephens reissued an overweight rating and set a $19.00 target price (up from $14.00) on shares of OraSure Technologies in a research note on Tuesday, July 11th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock has a consensus rating of Buy and an average price target of $15.46.

OraSure Technologies (NASDAQ OSUR) traded up 2.12% on Monday, hitting $20.73. The stock had a trading volume of 571,709 shares. The company has a market cap of $1.23 billion, a PE ratio of 38.32 and a beta of 1.57. OraSure Technologies has a 12 month low of $6.84 and a 12 month high of $21.59. The company has a 50-day moving average of $18.48 and a 200 day moving average of $14.08.

OraSure Technologies (NASDAQ:OSUR) last announced its quarterly earnings data on Wednesday, August 2nd. The medical instruments supplier reported $0.09 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.07 by $0.02. OraSure Technologies had a return on equity of 15.64% and a net margin of 22.29%. The firm had revenue of $40.18 million during the quarter, compared to analyst estimates of $36.54 million. During the same period in the previous year, the company earned $0.07 earnings per share. OraSure Technologies’s quarterly revenue was up 28.1% on a year-over-year basis. On average, analysts predict that OraSure Technologies will post $0.48 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “OraSure Technologies, Inc. (NASDAQ:OSUR) Downgraded by BidaskClub” was reported by BNB Daily and is the property of of BNB Daily. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://www.baseball-news-blog.com/2017/08/13/orasure-technologies-inc-nasdaqosur-lowered-to-hold-at-bidaskclub-updated.html.

In other news, EVP Anthony Zezzo II sold 72,916 shares of the stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $21.26, for a total transaction of $1,550,194.16. Following the sale, the executive vice president now directly owns 218,326 shares of the company’s stock, valued at $4,641,610.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Ronald H. Spair sold 510,112 shares of the stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $20.66, for a total transaction of $10,538,913.92. Following the sale, the chief financial officer now directly owns 208,606 shares in the company, valued at $4,309,799.96. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,036,670 shares of company stock valued at $19,807,152. Company insiders own 7.80% of the company’s stock.

A number of institutional investors have recently made changes to their positions in the stock. Alps Advisors Inc. boosted its position in shares of OraSure Technologies by 0.3% in the second quarter. Alps Advisors Inc. now owns 43,257 shares of the medical instruments supplier’s stock worth $747,000 after buying an additional 111 shares in the last quarter. PNC Financial Services Group Inc. raised its stake in shares of OraSure Technologies by 0.5% in the first quarter. PNC Financial Services Group Inc. now owns 46,588 shares of the medical instruments supplier’s stock worth $602,000 after buying an additional 242 shares during the last quarter. Profund Advisors LLC raised its stake in shares of OraSure Technologies by 2.8% in the second quarter. Profund Advisors LLC now owns 10,903 shares of the medical instruments supplier’s stock worth $188,000 after buying an additional 293 shares during the last quarter. Timber Hill LLC raised its stake in shares of OraSure Technologies by 3.2% in the second quarter. Timber Hill LLC now owns 11,597 shares of the medical instruments supplier’s stock worth $200,000 after buying an additional 363 shares during the last quarter. Finally, Wellington Management Group LLP raised its stake in shares of OraSure Technologies by 0.5% in the first quarter. Wellington Management Group LLP now owns 111,970 shares of the medical instruments supplier’s stock valued at $1,448,000 after buying an additional 587 shares during the last quarter. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

About OraSure Technologies

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Analyst Recommendations for OraSure Technologies (NASDAQ:OSUR)

Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply